Supplementary Tables – Indirect comparison of pembrolizumab monotherapy versus nivolumab+ipilimumab in first-line metastatic lung cancer

Name: Supplementary Tables – Indirect comparison of pembrolizumab monotherapy versus nivolumab+ipilimumab in first-line metastatic lung cancer
Creator: Future Science Group
Published: 2022-05-03 19:05:57
License: 暂无描述

DataCite Commons2022-05-03 更新2025-04-15 收录

下载链接：

https://future-science-group.figshare.com/articles/dataset/Supplementary_Tables_Indirect_comparison_of_pembrolizumab_monotherapy_versus_nivolumab_ipilimumab_in_first-line_metastatic_lung_cancer/19030124

下载链接

链接失效反馈

官方服务：

资源简介：

Table S1 Base case scenario of overall survival and progression-free survival in patients with PD-L1 TPS≥1% before matching Table S2 Landmark analysis of overall survival and progression-free survival for chemotherapy arms from KN024/KN042 and CheckMate 227 Part 1a in patients with PD-L1 TPS≥1% before and after matching Table S3 Pembrolizumab versus nivolumab+ipilimumab for overall survival and progression-free survival in patients with PD-L1 TPS≥1%, TPS≥50% and TPS 1–49%

提供机构：

Future Science Group

创建时间：

2022-05-03